Dr. Tehila Ben-Moshe shared the scientific rationale behind BND-67, a first-in-class anti-CD28 shedding antibody designed to preserve T-cell co-stimulation and restore effective anti-tumor immune responses.
BND-67 represents a differentiated immunotherapy approach, enhancing T-effector cell activation while inhibiting regulatory T-cell function. First-in-human studies are planned for Q2 2026.
https://www.sachsforum.com/11oif-agenda.html
